Pharma BD Deal Intelligence
Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion, at $20 per share in cash representing a total equity value of…
Novo Nordisk has concluded the acquisition of Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn. With the conclusion of the merger,…
Etavopivat met both co-primary endpoints in phase 3 HIBISCUS: 27% reduction in VOC events and superior haemoglobin response vs placebo in 385 people with SCD;…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novo Nordisk acquired Forma Therapeutics in 2022 (closed 9 Dec 2022) for approximately USD 1.1bn all-cash (USD 20/share) to gain etavopivat (FT-4202), an oral once-daily pyruvate kinase-R (PKR) activator for sickle cell disease (SCD), expanding Novo Nordisk's rare blood disorders pipeline. The thesis was validated in April 2026: on 20 April 2026 Novo Nordisk reported that the pivotal phase 3 HIBISCUS trial (52 weeks, etavopivat 400 mg once-daily vs placebo, n=385, ages 12+) met both co-primary endpoints — a 27% reduction in vaso-occlusive crisis events (median time to first VOC 38.4 vs 20.9 weeks) and a haemoglobin response of >1 g/dL at 24 weeks in 48.7% of treated patients vs 7.2% on placebo. Etavopivat is the first PKR activator to succeed in a phase 3 SCD trial, and Novo Nordisk plans its first regulatory submission in the second half of 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (this deal) | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2022 deals · Novo Nordisk A/S deals · Hematology deals